QS Research · Michael Burry's Scion Capital analyst template · 2006
EXELIXIS, INC. (EXEL)
As of 2026-11-18 · 12/15 boxes filled from SEC filings and market data
Report price $68.29 (close 2026-11-18); latest close $64.63 (2026-11-20), -5.4% since the report; figures re-marked at the latest close
Conclusion: BUY
Conviction medium · base case +41% · downside -19% · upside +43%
At $68.29 Exelixis trades at 18.8x TTM net income, and the market is pricing -4.5% annual revenue for 10 years even though the latest fiscal year grew +7.0%; that gap is the reverse-DCF arithmetic, not a forecast. The call is BUY because the cash generation is not reflected in that price: TTM free cash flow is $1.16B, the FCF yield is 7.0%, net cash is $1.40B, and the net buyback yield is 7.57%, while the zanzalintinib PDUFA on March 3, 2027 and the Federal Circuit patent affirmance are dated supports. The downside assumes a 10.0% earnings decline at a compressed P/E of 15.98x (today 18.8x), giving -23.5% to $52.24. The base assumes P/E at 25.03x, the company's own median P/E over five fiscal years, giving +33.1% to $90.92. The upside assumes +35% earnings at today's P/E of 18.8x, giving +35.0% to $92.19. The moat is narrow and CABOMETYX concentration is real, so this is a cash-return and catalyst call rather than a durable-compounder call.
Key numbers
- Share price: $64.63
- Market cap: $15.77B
- Latest financial period: TTM to Oct 2, 2026
- Revenue (TTM): $2.50B
- EV / EBITDA (TTM): 13.9x
- P/E (TTM): 17.8x
- FCF yield: 7.4%
- Price / book: 8.60x
- Earnings-quality flags (TTM): none flagged
- EV / FCF (TTM): 12.3x
- Revenue growth (latest fiscal year): +7.0%
- ROIC (TTM): above 100% (not meaningful)
- WACC: 7.3%
- Economic profit spread: +92.7 pts
The 15 boxes
- ✓ 1. Long-form business notes
Exelixis (filed earlier as Exelixis Inc until 2012-09-12) is a commercial oncology company whose revenue is dominated by cabozantinib product sales and ex-U.S. royalties. The latest 10-K describes four marketed products, nine consecutive years of annual profitability through 2025, and a pipeline led by zanzalintinib under FDA review for colorectal cancer. Between the oldest and newest annual reports, revenue scale, royalties, approved indications and pipeline breadth all increased, while the business remains concentrated in CABOMETYX and COMETRIQ.
- ✓ 2. Competitive advantage
EXEL has a narrow, not durable, competitive advantage. CABOMETYX is approved by the FDA and in 68 other countries and holds a Category 1 NCCN first-line RCC recommendation, and the company has real scale: operating income reached $1.00B on $2.50B TTM revenue to 2026-10-02, with $1.17B TTM operating cash flow. But the franchise depends on one molecule, competes with larger rivals and generic risk, and ex-U.S. commercialization is controlled by Ipsen and Takeda. The six-period record shows positive operating income throughout, so the advantage is real but not wide.
- ✓ 3. 10-Q takeaways
Q3 2026 (quarter ended September 30, 2026) total revenues rose 10% to $658.7 million, with net product revenues of $604.9 million (+11%) led by CABOMETYX at $603.2 million (+12%) on 6% unit growth and a 5% higher average net selling price; gross margin slipped to 96% from 97%. R&D ($209.5 million) and SG&A ($154.6 million) both rose, yet GAAP net income was $218.1 million ($0.85 diluted) and non-GAAP $240.2 million ($0.94 diluted). FY2026 guidance is unchanged on revenue at $2.500–$2.550 billion total and $2.300–$2.350 billion net product, with the effective tax rate cut to 16%–18%, and the 10-Q reports no material change to risk factors. The company used $402.1 million of its $750 million May 2026 repurchase authorization through September 30, 2026 at an average $54.03 per share.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.